Markets India

Sahajanand Medical Technologies has set its IPO price band at Rs 327-344 per share, with the offer for sale (OFS) opening on October 15. The Rs 475.48 crore IPO, which does not raise capital for the company, will list on BSE and NSE on October 22.

Sahajanand Medical Tech Sets IPO Price Band at Rs 327-344 per Share

Sahajanand Medical Technologies’ Rs 475.48 crore IPO is structured entirely as an OFS, with 1,38,22,116 equity shares available for sale. Proceeds will go to selling shareholders, including Shree Hari Trust and Kotak Pre-IPO Opportunities Fund. The allocation will prioritize retail investors, with at least 35% reserved for them and 15% for non-institutional investors, while qualified institutional buyers may receive up to 50%.

The company’s FY26 financials highlight its growth trajectory: profit after tax surged 174.6% to Rs 69.082 crore, and revenue from operations rose 18.1% to Rs 1,210.504 crore. For the three months ended June 30, 2026, it reported Rs 15.087 crore in profit and Rs 351.669 crore in revenue. These figures underscore its strong performance, which could influence investor sentiment.

The OFS structure shifts focus to investor allocation dynamics rather than capital raising. Retail prioritization may boost participation but leaves the IPO’s subscription success uncertain. Selling shareholders will receive proceeds, while market perceptions of the company’s valuation could be shaped by allocation patterns.

Stakeholders, including retail investors and non-institutional buyers, will see varying allocation percentages. The company’s financial health and market position remain key factors for all participants, though the Brief does not mention specific risks or opportunities.

The three-day subscription window closes on October 19, 2026. The basis of allotment is expected to be finalized on October 20, with shares listing on BSE and NSE on October 22, 2026.

Sahajanand Medical Technologies’ IPO, structured as an OFS, prioritizes retail investors with a price band of Rs 327-344 per share. While its strong FY26 performance supports investor interest, the subscription outcome remains uncertain.

Topics: IPO, Offer For Sale, Retail Investors, Financial Performance, Medical Technology, Stock Market, IPO Subscription, BSE NSE

#IPONews #MedicalTech #StockMarket #OfferForSale #RetailInvestors #FY26Results #BSENSE

Source: ET Markets